Overview

Feasibility Study of Metformin Therapy in ADPKD

Status:
Completed
Trial end date:
2020-08-17
Target enrollment:
Participant gender:
Summary
This study is being done to determine if treatment with metformin, a drug widely used for the treatment of diabetes type 2, is safe and well tolerated by individuals with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who are not diabetic and who have slightly decreased kidney function. The study will also evaluate the effects of metformin on kidney growth and kidney function.
Phase:
Phase 2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Metformin